Shots:

• STADA to acquire Biopharma’s pharmaceutical prescription and consumer health business including local manufacturing operations and ~300 new staff. Biopharma will retain its blood plasma-based business and will focus on its development both in Ukraine and outside Ukraine
• The acquisition will complement STADA’s European growth strategy and allow STADA to become a major pharma player in Ukraine. The transaction is expected to be close in Dec’2019
• The acquisition follows STADA’s purchase of six GSK OTC products in August 2019 and its acquisitions of the EMEA distribution rights to Nizoral and controlling stakes in Pymepharco and Bioceuticals in 2018

Click here to­ read full press release/ article | Ref: STADA | Image:  STADA